Home
Contact
Papers
News
Rome, Italy |
info@neomatrixbiotech.com
|
Home
Contact
Papers
News
Personalizing cancer Immunotherapy with our DNA
Where we are
Preclinical studies completed
Biomarker assay under advanced development
Specialty Oncology Centers / KOLs identified and ready to start
Cancer Targets
Melanoma
Lung Cancer
Brands and Partners
Our Partners
Takis
Evvivax
Vitares
Reference
The perfect personalized cancer therapy: cancer vaccines against neoantigens.
Aurisicchio L, Pallocca M, Ciliberto G, Palombo F.
J Exp Clin Cancer Res. 2018 Apr 20;37(1):86. doi: 10.1186/s13046-018-0751-1
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874958
© 2023 NEOMATRIX SRL | P. IVA 15698291000 | ALL RIGHTS RESERVED